Evidence map›Paper›PMID 41309056›Full record

ArticleJournal of biomedical research2026

Isolation of neutralizing antibodies against SARS-CoV-2 through an epitope-guided negative screening by phage display.

Ming Lu, Yin Chen, Xiaoyu Liu, Fang Gao, Liming Gou, Wei Ye, Jiaqi Wen, Xiling Guo, Wei Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Editorial commentary on the special issue of immunology.Journal of biomedical research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ming LuNational Health Commission Key Laboratory of Antibody Technique, School of Basic Medical Sciences, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Yin ChenKey Laboratory of Enteric Pathogenic Microbiology; Ministry of Health Institute of Pathogenic Microbiology; Jiangsu Province Center for Disease Control and Prevention, Nanjing, Jiangsu 211166, China.
Xiaoyu LiuNational Health Commission Key Laboratory of Antibody Technique, School of Basic Medical Sciences, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Fang GaoNational Health Commission Key Laboratory of Antibody Technique, School of Basic Medical Sciences, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Liming GouNational Health Commission Key Laboratory of Antibody Technique, School of Basic Medical Sciences, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Wei YeNational Health Commission Key Laboratory of Antibody Technique, School of Basic Medical Sciences, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Jiaqi WenNational Health Commission Key Laboratory of Antibody Technique, School of Basic Medical Sciences, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Xiling GuoKey Laboratory of Enteric Pathogenic Microbiology; Ministry of Health Institute of Pathogenic Microbiology; Jiangsu Province Center for Disease Control and Prevention, Nanjing, Jiangsu 211166, China.
Wei GaoNational Health Commission Key Laboratory of Antibody Technique, School of Basic Medical Sciences, Animal Core Facility of Nanjing Medical University, Nanjing Medical University, Nanjing, Jiangsu 211166, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutralizing antibodies are essential tools in antiviral therapy and epidemic preparedness, capable of directly inhibiting viral entry and limiting disease progression. However, traditional antibody discovery strategies-such as animal immunization or B cell isolation from infected individuals-are often hindered by biosafety concerns, lengthy development timelines, and limited adaptability during outbreaks. In the present study, we aimed to establish a robust and rapid

Indexed as

epitope-guidedneutralizing antibodyphage displaySARS-CoV-2

Identifiers

PMID41309056
PMCPMC13044406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.